|
|
|
|
Updates to managing COVID-19 guideline
We've:
|
|
|
We are continuously updating our COVID-19 guidelines to incorporate the latest evidence and keep abreast of new developments in diagnoses and treatments. We’ll highlight recent updates in this monthly email communication, or you can keep up to date on the latest live changes through our website.
|
|
|
|
We've recommended icosapent ethyl for reducing the risk of cardiovascular events in adults with raised triglycerides. 425,000 people with controlled low-density lipoprotein cholesterol, who are taking a statin and have raised levels of triglycerides, could benefit from this treatment. Until now, there have been no medicines for people at risk of cardiovascular events who have raised levels of triglycerides despite having statins with or without ezetimibe (another type of anti-cholesterol medicine).
|
|
|
People with lived and work experience of social work have developed new evidence-based guidance on this topic. The guideline covers planning, delivery and review of interventions, how inequalities can be reduced and support for social workers in multidisciplinary teams. It’s aimed at a wide-range of people including social workers, social care staff, healthcare workers and educators. It is also useful for adults with complex needs (including self-funders), their families or carers, and the public.
|
|
|
We've recommended imlifidase for people who are waiting for a kidney transplant and who are highly sensitised to human leukocyte antigens (HLAs). People who are highly sensitised to HLAs have a greater risk of the body rejecting the donor organ. Blood transfusions, blood type and pregnancy are some of the risk factors that can increase the chances of developing an HLA sensitisation. People from Black, Asian or minority ethnic family backgrounds, and people who have been pregnant, are more likely to be highly sensitised.
|
|
We've recommended teduglutide for people who are in a stable condition following surgery to remove an abnormal bowel. Teduglutide helps to improve the absorption of nutrients and fluid from the remaining intestine. Clinical trial evidence shows that teduglutide reduces the number of days a week people with short bowel syndrome need parenteral support compared with placebo.
|
|
New social work guideline to help support adults experiencing complex needs
In this month’s NICE Talks podcast, we discuss the positive impact our new guidance will have on people using social work services. Joining the discussion are members of the guideline committee that developed our recommendations.
|
|
|
Working together for disabled children and young people
We’ve published a new quick guide on developing a positive working culture for supporting disabled children and young people with severe complex needs. It’s aimed at social workers and social care practitioners and includes information on:
- inter-agency teams
- positive working culture
- learning together
- key working support.
“This new quick guide from NICE will support social care staff to work together, ensuring the views, ambitions and preferences of the child are at the centre of planning and decision making.” Jennifer Sebright, senior social worker, Leeds Children’s Social Work Services
|
|
|
Help shape new advisory service for artificial intelligence and data-driven technologies
We’re placing user needs front and centre to develop a new service to support the development and adoption of artificial intelligence and data-driven technologies in health and care.
We are beginning to build a web platform for the service and need potential users to work with us to test, develop and improve it. We are particularly keen to hear from:
- social care providers
- commissioners (especially those working in a leadership role within integrated care systems).
|
|
Easy read guides
Our easy read guides provide accessible information for people who have difficulty with reading. We encourage health and social care practitioners to share these guides with the people they support:
|
|
Comment on our draft advocacy services guideline
We’ve published draft guidance on advocacy services for adults with health and social care needs. It includes recommendations on:
- commissioning and delivery
- identifying who should be offered advocacy
- providing good advocacy
- monitoring and improving services
- training and skills.
"This guidance will provide an important resource for advocates, advocacy organisations, commissioners and health and care professionals to review and improve how they facilitate and deliver advocacy." Jonathan Senker, chief executive at VoiceAbility and NICE guideline committee member
The consultation closes at 5pm, Tuesday 19 July 2022.
|
|
Comment on a consultation
Our current consultations include:
|
|
|
Consultation is a key part of our guidance development process. It enables those with an interest in our guidance to comment at specific stages and feedback into the decision-making process.
|
|
Join a committee
We have a number of vacancies for health and care professionals and lay members to join our committees. Topics include sepsis, falls in older people, diabetes and harmful gambling. Join us and have an active role in producing a guideline or quality standard.
|
|
Observe a meeting
Our advisory committee meetings, technology appraisal appeal hearings and public board meetings are open to the public. Holding them in public supports our commitment to having processes in place that are rigorous, open, and transparent.
We’re currently holding all our public meetings virtually.
|
|
Increasing the capacity of our technology appraisals - the proportionate way
We are trialling a new, proportionate approach to technology appraisals. We expect that this will increase our capacity by 20% from 2023/24. You can read more about the approach and its potential impact in this blog from Jenniffer Prescott, NICE's programme director of health technology appraisals process and operations.
|
|
|
A ‘safe space’ for addressing complex health technology assessment challenges
We’re developing a collaborative space for research and development to help us develop new methods and processes for health technology assessment. You can read about our new health technology innovation and assessment laboratory in a blog by Nick Crabb, NICE's programme director of scientific affairs.
|
|
|
Early value assessment for medical technologies event
Join us to hear about our new approach to providing early value assessment for medical technologies:
- Driving innovation into the hands of health and care professionals, Monday 18 July 2022, 11am to 12noon, online.
Through early value assessment, we'll offer rapid assessments of the most promising and impactful digital products, devices and diagnostics where the evidence base is still emerging. We will produce these assessments more quickly than our existing medical technologies guidance. We will also provide expert judgement about what further real world evidence needs to be collected when the product is introduced to the NHS, for a full evaluation later.
This month, we'll begin assessment of our first 2 pilot topics - digital apps for depression and anxiety in children. We aim to publish these in October. Other topics will follow in adult mental health, early cancer diagnosis and cardiovascular disease.
|
|
Our business plan for 2022 to 2023
We’ve published our business plan for the year ahead. It explains our priorities and outlines 4 key objectives:
- Improving the usefulness and usability of our guidelines by developing digital living guideline recommendations for breast cancer, with a new model of support for adoption of best practice.
- Expanding our capacity by 20% through developing a more proportionate approach to our technology appraisal guidance for medicines.
- Actively drawing in medical devices, diagnostics and digital products that address national unmet needs and providing quicker assessments of early value to identify the most promising technologies conditional on further evidence generation.
- Transformation of the way we work, including our technology, processes and behaviours.
|
|
Join the World Evidence-Based Healthcare (EBHC) Day 2022 campaign
World EBHC Day takes place on Friday 20 October. This year, the campaign focuses on partnerships for purpose and how partnerships can bridge research, policy and practice to realise the potential of evidence-based healthcare.
As an official partner, we're encouraging you to take part. Get involved by becoming an evidence ambassador or by sharing your experience about partnerships in evidence-based healthcare through a blog or short video.
|
|
|
|
|
|
|
